Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acquired Stada To Act As 'Core' For Future Bain and Cinven Bolt-Ons

Executive Summary

Cinven and Bain seem likely to use German generics maker Stada as a nucleus around which to add smaller acquisitions, mostly in Europe, for an eventual exit by the private equity firms.

You may also be interested in...



Try, Try Again: Bain And Cinven File Fresh Bid For Stada

Stada is likely to approve a second takeover bid from equity groups Bain and Cinven soon, at a new price of €66.25 per share; an offer cleared by Germany's stock market authorities despite a ban in the country on repeat acquisition bids within 12 months.

Try, Try Again: Bain And Cinven File Fresh Bid For Stada

Stada is likely to approve a second takeover bid from equity groups Bain and Cinven soon, at a new price of €66.25 per share; an offer cleared by Germany's stock market authorities despite a ban in the country on repeat acquisition bids within 12 months.

Stada CEO & CFO Resign; Rumors Circle Of A New Takeover bid

Stada's top brass have quit following rumors earlier this week of a fresh takeover bid for the generic company from equity groups Bain and Cinven; ex-Boehringer executive Tjeenk Willink has been named incoming CEO.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC098543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel